Corporate Governance

Management Team


Patients are at the heart of everything we do at Loxo Oncology, and we continue to be motivated by one goal: to dramatically improve the lives of people living with cancer by developing medicines against genetically defined targets driving cancer growth. Though drug development can be risky and complicated, we work hard to navigate through these complexities for the benefit of patients.

  • Joshua H. Bilenker, M.D.
    Joshua H. Bilenker, M.D.
    Chief Executive Officer
  • Jacob S. Van Naarden
    Jacob S. Van Naarden
    Chief Business Officer
  • Jennifer Burstein, CPA
    Jennifer Burstein, CPA
    VP of Finance
  • Nisha Nanda, Ph.D.
    Nisha Nanda, Ph.D.
    Senior VP, Development Strategy
  • Sara Slifka
    Sara Slifka
    VP, Business Operations & Program Management
  • Michael Rothenberg, M.D., Ph.D.
    Michael Rothenberg, M.D., Ph.D.
    VP, Research and Development
  • Nora Ku
    Nora Ku
    Senior Medical Director
  • Deborah Morosini, M.D.
    Deborah Morosini, M.D.
    VP, Clinical Affairs and Patient Engagement
  • Anne Frederick, Ph.D.
    Anne Frederick, Ph.D.
    VP, Regulatory Affairs
  • Katie Cairati
    Katie Cairati
    Executive Director, Regulatory Affairs
  • Michael Cox
    Michael Cox
    Senior Director, Clinical Development and Medical Affairs

Dr. Joshua H. Bilenker, M.D., founder of Loxo Oncology, serves as President and Chief Executive Officer, and sits on the board of directors.

Previously, Dr. Bilenker was a Partner at Aisling Capital, a multi-strategy healthcare investment firm based in NY, where he remains an Operating Partner.

From 2004-2006, Dr. Bilenker was a Medical Officer at the U.S. FDA in the Office of Oncology.

Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. He received his M.D. from The Johns Hopkins School of Medicine and his A.B. degree from Princeton University.

Jacob S. Van Naarden serves as Chief Business Officer. In his previous roles, Mr. Van Naarden served in various biotechnology investing, operating, and advisory capacities.

Previously, Mr. Van Naarden served as a public equity biotechnology analyst at HealthCor Management, a multi-billion dollar healthcare-dedicated investment firm based in NYC. Prior to HealthCor, Mr. Van Naarden was an Associate at Aisling Capital, a multi-strategy healthcare investment firm based in NY. Mr. Van Naarden started his career in the Healthcare Group of the Investment Banking Division at Goldman Sachs.

Mr. Van Naarden received his A.B. degree in molecular biology from Princeton University, graduating magna cum laude and Phi Beta Kappa.

Jennifer Burstein serves as VP of Finance.

Prior to Loxo Oncology, Ms. Burstein served as Vice President of Finance at Acorda Therapeutics, Inc., a public biotechnology company, from July 2010 until April 2015, where she held several positions of increasing responsibility in Finance from 2006 until being appointed Vice President of Finance.

Prior to joining Acorda, from 2002 to 2006, she was with Eyetech Pharmaceuticals, Inc., a public biotechnology company, which is currently a subsidiary of Valeant Pharmaceuticals International, Inc., where she held several positions of increasing responsibility in Finance until being promoted to Senior Director, Accounting. Before Eyetech, Ms. Burstein worked in the Finance departments at several companies and in public accounting.

Ms. Burstein received her B.S. in Business Administration and M.B.A. in Accounting from the State University of New York at Buffalo and has a CPA license in New York.

Dr. Nanda serves as Senior Vice President of Development Strategy. Dr. Nanda has had increasing roles of responsibility in both clinical and pre-clinical development. Most recently Dr. Nanda worked on the clinical development of carfilzomib (Kyprolis) and the approval of omacetaxine (Synribo).

Dr. Nanda’s career in drug development has included roles at Onyx, ChemGenex, Portola, Millennium and Cor.

Dr. Nanda has a BSc Hons in Biochemistry and Molecular Genetics from UNSW, Sydney, Australia and a PhD in Biochemistry and Molecular Genetics from UNSW and the Victor Chang Cardiac Research Institute, Sydney, Australia.

Sara Slifka serves as Vice President of Business Operations and Program Management. Previously, Ms. Slifka was a Vice President in Equity Research at Morgan Stanley covering the biotech sector.

In her prior role, Ms. Slifka analyzed small and large cap biotechnology companies from a financial, clinical, regulatory and commercial perspective.

Ms. Slifka received her A.B. degree from Princeton University.

Dr. S. Michael Rothenberg, M.D., Ph.D., serves as Vice President of Research and Development.

Previously, Dr. Rothenberg was a medical oncologist and cancer researcher at Massachusetts General Hospital.

Dr. Rothenberg trained at Massachusetts General Hospital in internal medicine and at the Massachusetts General Hospital Cancer Center and the Dana Farber Cancer Institute in medical oncology, earning board certification in these specialties. He received his M.D. and Ph.D. degrees from the Stanford University School of Medicine, and his B.A. degree in Chemistry from Yale University.

Dr. Ku serves as a Senior Medical Director for Loxo Oncology.

Her career in academic and community practice included active involvement in clinical research as a clinical investigator. Prior to joining Loxo Oncology Dr. Ku worked with a specialty consulting group supporting projects facilitating drug development by large and small pharmaceutical company clients.

Dr. Ku is a graduate of the UCLA School of Medicine. She completed her residency in Internal Medicine at UT Southwestern Medical Center and returned to UCLA to complete a combined fellowship in Hematology and Oncology. She is board certified in Internal Medicine and Medical Oncology.

Dr. Deborah Morosini M.D., MSW, serves as Vice President of Clinical Affairs and Patient Engagement.

Previously, Dr. Morosini was a VP at Foundation Medicine, a cancer genomics and molecular information company in Cambridge, MA. From 2007-2012, Dr. Morosini led the molecular pathology group at AstraZeneca Pharmaceuticals.

She is a seasoned patient advocate, serving on multiple national non-profit boards.

Dr. Morosini trained at Boston University School of Medicine in anatomic and clinical pathology, where she served as chief resident. She received her M.D. from Boston University School of Medicine, her Masters in Social Work from New York University and her BA in English from Mount Holyoke College.

Dr. Frederick serves as Vice President of Regulatory Affairs. Prior to joining Loxo Oncology, Dr. Frederick worked on the global registration strategy and approval of ceritinib (ZYKADIA) while at Novartis Oncology.

Dr. Frederick’s career in Regulatory Affairs has included roles at Roche, Pfizer, Innovive, and Novartis Oncology.

Dr. Frederick has a BA in Chemistry from Kalamazoo College (Kalamazoo, Michigan) and a PhD in Chemistry from Yale University.

Ms. Cairati serves as Executive Director, Global Regulatory Affairs. Ms. Cairati’s career spans many aspects of drug development including regulatory affairs, clinical development, data management and manufacturing.

Previously Ms. Cairati has held increasing roles of responsibility at Genentech, Pharmacyclics and ChemGenex in addition to establishing her own consulting firm, Cairati Consulting Inc.

Ms. Cairati received her MS degree from University of California, Davis.

Dr. Cox serves as Senior Director, Clinical Development and Medical Affairs. Dr Cox has been involved in the product launches and life cycle management of numerous oncology products including radium-223 (Xofigo®), regorafenib (Stivarga®), sorafenib (Nexavar®) cetuximab (Erbitux®), denosumab (XGEVA®) and darbepoetin alfa (Aranesp®).

Dr. Cox joined Loxo Oncology from Bayer Consumer Care AG, Basel, Switzerland where he served as Medical Affairs Early Pipeline Lead, Oncology for Region Europe/Canada and Emerging Markets. Prior to Bayer, he held global medical affairs positions at Merck KGaA, Darmstadt, Germany and Amgen, Inc., Thousand Oaks, California.

Dr. Cox received his Pharm.D. from Ohio Northern University and a MHSc in Clinical Research from Duke Unviersity’s School of Medicine. Dr. Cox completed pharmacy practice residencies at Mission Hospitals in Asheville, North Carolina and the University of Pittsburgh Cancer Institute – University of Pittsburgh Medical Cancer, Pittsburgh, Pennsylvania. He completed a medical oncology/clinical drug development fellowship in the Clinical Pharmacology Section, Center for Cancer Research at the National Cancer Institute, Bethesda, Maryland. He is a Board Certified Oncology Pharmacist.

Board of Directors


  • Joshua H. Bilenker, M.D.
    Chief Executive Officer
  • David Bonita, M.D.
  • Steve Elms
  • Keith T. Flaherty, M.D.
    Director, and Chair of the SAB
  • Avi Z. Naider
  • Lori A. Kunkel, M.D.
  • Alan Fuhrman
  • Tim Mayleben
  • Steve D. Harr, M.D.

Dr. Joshua H. Bilenker, M.D., founder of Loxo Oncology, serves as President and Chief Executive Officer, and sits on the board of directors.

Previously, Dr. Bilenker was a Partner at Aisling Capital, a multi-strategy healthcare investment firm based in NY, where he remains an Operating Partner.

From 2004-2006, Dr. Bilenker was a Medical Officer at the U.S. FDA in the Office of Oncology.

Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. He received his M.D. from The Johns Hopkins School of Medicine and his A.B. degree from Princeton University.

Dr. David Bonita has served on the board of directors since September 2013.

Dr. Bonita is currently a Private Equity Partner at OrbiMed, where he serves on the boards of Clementia, Tricida, ViewRay, SI Bone, Acutus Medical Inc., Cryterion, Kyn Therapeutics, Prelude Therapeutics Inc., and Keystone Heart.

He previously served on the board of Enobia, Ambit Biosciences and CardiAQ. Prior to joining OrbiMed, Dr. Bonita worked in the healthcare investment banking groups of Morgan Stanley and UBS. He has published several scientific articles in peer-reviewed journals based on research performed at the Harvard Medical School.

Dr. Bonita received his A.B. degree magna cum laude in Biological Sciences from Harvard University and his joint M.D./M.B.A. from Columbia University where he was elected to the Alpha Omega Alpha Medical Honor Society and Beta Gamma Sigma Business Honor Society.

Mr. Steve Elms has served on the board of directors since July 2013.

Mr. Elms is currently a Managing Partner at Aisling Capital, a leading private equity fund investing in life science companies, and serves on the board of a number of public and private life sciences companies.

Previously, Mr. Elms was a senior member of the Life Sciences Investment Banking Group of Hambrecht & Quist and was involved in over 60 financing and M&A transactions, which helped clients raise in excess of $3.3 billion in capital. His previous healthcare sector experience includes over two years as a pharmaceutical sales representative for Marion Laboratories.

Mr. Elms received an M.B.A. from the Kellogg Graduate School of Management at Northwestern University, and a B.A. in Human Biology from Stanford University.

Dr. Keith T. Flaherty has served as SAB Chair since company inception, and sits on the board of directors.

Dr. Flaherty is currently Director of Clinical Research and the Henri and Belinda Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, and is a Professor of Medicine at Harvard Medical School.

Dr. Flaherty trained in internal medicine at Brigham and Women’s Hospital, and in medical oncology at the University of Pennsylvania, earning board certification in these specialties.

He received his M.D. from The Johns Hopkins School of Medicine and his B.S. degree from Yale University.

Mr. Avi Z. Naider has served on the board of directors since September 2013.

Mr. Naider is currently Chairman and CEO of ACES Risk Management Corp.

Mr. Naider is a successful entrepreneur who has founded and managed companies in various sectors, including internet advertising and mortgage industry software. He previously worked in private equity and for the Boston Consulting Group.

Mr. Naider received his A.B. from the Woodrow Wilson School of Public and International Affairs at Princeton University, where he graduated Phi Beta Kappa.

Dr. Lori A. Kunkel has served on the board of directors since October 2014.

Dr. Kunkel served as Acting Chief Medical Officer for Loxo Oncology from October 2013 to October 2014.

As principal of LAK 505, LLC, she is a clinical/regulatory strategic advisor to public and private biotech companies in the San Francisco, San Diego, New York and Boston areas. She currently serves on the board of directors of Curis, Inc, Tocagen and Maverick Therapeutics and is a clinical advisor to Amphvena, Atreca and Verastem. Dr Kunkel served as Chief Medical Officer at Pharmacyclics, Inc. leading integrated clinical development highlighted by the approval of IMBRUVICA. She has also served as Chief Medical Officer at Proteolix Inc. (acquired by Onyx), Syndax, and ACT Biotech.

Prior to joining the international biotechnology industry in 1995, Dr. Kunkel spent ten years in academic/clinical medicine and served as a faculty member in the Division of Hematology/Oncology’s Bone Marrow Transplant Unit at University of California, Los Angeles.

She trained in internal medicine at Baylor College of Medicine, hematology at USC and oncology at UCLA, earning board certifications in these specialties.

Alan Fuhrman has served on our board of directors since January 2015.

Mr. Fuhrman currently serves as CFO of Mirna Therapeutics (Nasdaq:MIRN) an oncology drug development company. He was CFO of Ambit Biosciences from October 2010 until its sale to Daiichi Sankyo in November 2014.

Prior to this role, he served as CFO of Naviscan, Inc., a privately-held medical imaging company from November 2008 until September 2010, and as CFO of Sonus Pharmaceuticals from September 2004 until August of 2008. Earlier in Mr. Fuhrman’s career he practiced as a CPA with Coopers & Lybrand.

Mr. Fuhrman received B.S. degrees in both business administration and agricultural economics from Montana State University.

Tim Mayleben has served on the board of directors since July 2015.

Mr. Mayleben is currently President and Chief Executive Officer at Esperion Therapeutics and has been a member of the board of directors since 2010.

Mr. Mayleben is an advisor to, investor in, and member of the board of directors of several life science companies, including Kaleo Pharma, Lycera Corporation, Marinus Pharmaceuticals and the Wolverine Venture Fund.

Tim earned an MBA, with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a BBA from the University of Michigan, Ross School of Business.

Dr. Steve D. Harr joined the board of directors in November 2016.

Dr. Harr is currently the chief financial officer and head of corporate development at Juno Therapeutics, a biopharmaceutical company developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies.

Previously, Dr. Harr was managing director and head of biotechnology investment banking at Morgan Stanley. Prior to his investment banking role at Morgan Stanley, Dr. Harr was Morgan Stanley’s lead biotech research analyst and co-head of Global Healthcare Research.

Dr. Harr received a B.A. in economics from College of the Holy Cross and an M.D. from The Johns Hopkins University School of Medicine. Dr. Harr was a resident in internal medicine at the University of California, San Francisco.

Governance Documents


The Board of Directors of Loxo Oncology, Inc. (the “Company”) sets high standards for the Company’s employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company’s business.

To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.

Committee Composition


Audit
Compensation
Nominating & Governance
Joshua H. Bilenker, M.D.
David Bonita, M.D.
Avi Z. Naider
Steve Elms
Keith T. Flaherty, M.D.
Lori A. Kunkel, M.D.
Alan Fuhrman
Tim Mayleben
Steve D. Harr, M.D.
 = Chair
 = Member

Contact the Board


You can contact Loxo Oncology, Inc.'s Board of Directors to provide comments, to report concerns, or to ask a question, at the following address.

Corporate Secretary
Loxo Oncology, Inc.
281 Tresser Blvd, 9th Floor
Stamford, CT 06901 

United States

You may submit your concern anonymously or confidentially by postal mail. You may also indicate whether you are a shareholder, customer, supplier, or other interested party.

Communications are distributed to the Board, or to any individual directors as appropriate, depending on the facts and circumstances outlined in the communication. In that regard, the Loxo Oncology, Inc. board of directors has requested that certain items which are unrelated to the duties and responsibilities of the board should be excluded, such as:

  • Product complaints
  • Product inquiries
  • New product suggestions
  • Resumes and other forms of job inquiries
  • Surveys
  • Business solicitations or advertisements

In addition, material that is unduly hostile, threatening, illegal or similarly unsuitable will be excluded, with the provision that any communication that is filtered out must be made available to any non-management director upon request.

Email Alerts

Receive alerts for Press Releases, Events & Presentations, SEC Filings & EOD Stock Quote

Sign up